Friday, July 27, 2018

3 Casino Stocks to Buy Now

Perhaps it is because trading stocks can often mirror the thrill of winning big at the blackjack tables, or maybe it is because Las Vegas conjures images of the world’s most flashy brands and businessmen. Regardless of the reason, it is clear that gambling stocks are always among the most popular on Wall Street.

Luckily for investors, now is also an interesting time to be buying gambling stocks, as continued Vegas strength, legalized sports gambling coming to the U.S., and an overall international interest in gaming has created some interesting buying opportunity.

Of course, no industries are without risk, and recently, some casino giants have been selling off as gambling data has hinted at a potential slowdown in Macau after an extended recovery in the world's top gaming hotspot.

Still, we can use Zacks’ proven stock-picking methods to find solid stocks in any industry. Check out these casino stocks today:

1. Penn National Gaming, Inc. ((PENN ) )

Penn National Gaming is an operator of a number of casino and gambling properties in North America, specifically located in smaller markets and non-Vegas gambling hotspots. Recently, analysts at Morgan Stanley called the Supreme Court gambling verdict as a “slight positive for regional gaming stocks” and named PENN as one that could benefit the most.

Penn National is also currently holding a Zacks Rank #1 (Strong Buy). The stock has also been one of the hottest gaming picks on Wall Street recently, surging more than 19% in the past three months and nearly 71% in the last year. Still, with new growth catalysts ahead, PENN could very well break higher.

 

2. Red Rock Resorts, Inc. ((RRR ) )

Based in Las Vegas, Red Rock Resorts operates 22 casino and entertainment properties throughout the country. The company is also leader in the Native American gambling industry, managing such facilities in California and Michigan. In other words, RRR gives investors exposure to traditional gaming hubs and budding growth markets.

RRR is sporting a Zacks Rank #2 (Buy), as well as a “B” grade for Growth and an “A” grade for Momentum in our Style Scores system. Earnings growth is projected to hit a staggering 112% this year, and the stock has soared nearly 18% in the past three months. RRR could keep surging higher, as its EPS estimates have added 10% recently, signaling bullish analyst sentiment.

 

3. Boyd Gaming Corporation ((BYD ) )

Also based in Vegas, Boyd Gaming is an owner and operator of 24 gaming properties in seven states. Investors will hope that these strategically-located facilities can position the company to capitalize on legalized sports gambling in the near future, and with the stock sporting a Zacks Rank #2 (Buy) right now, this stock could already be surging soon. Also, Boyd is expected to improve its EPS figures by 28% in 2018.

 

Want more market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Here >>

Friday, July 20, 2018

Blakecoin Hits Market Capitalization of $269,871.00 (BLC)

Blakecoin (CURRENCY:BLC) traded 8.9% lower against the U.S. dollar during the 24 hour period ending at 19:00 PM ET on July 19th. Over the last seven days, Blakecoin has traded 0% higher against the U.S. dollar. Blakecoin has a market cap of $269,871.00 and $130.00 worth of Blakecoin was traded on exchanges in the last 24 hours. One Blakecoin coin can currently be bought for about $0.0143 or 0.00000192 BTC on exchanges including Cryptopia and C-Patex.

Here is how similar cryptocurrencies have performed over the last 24 hours:

Get Blakecoin alerts: Bitcoin (BTC) traded 1.5% higher against the dollar and now trades at $7,462.30 or 1.00000000 BTC. Ethereum (ETH) traded down 1.9% against the dollar and now trades at $469.69 or 0.06291890 BTC. Bitcoin Cash (BCH) traded 0.1% lower against the dollar and now trades at $825.63 or 0.11060100 BTC. Litecoin (LTC) traded down 0.1% against the dollar and now trades at $86.78 or 0.01162480 BTC. Monero (XMR) traded up 0.5% against the dollar and now trades at $139.89 or 0.01873990 BTC. Ethereum Classic (ETC) traded 0.3% higher against the dollar and now trades at $17.38 or 0.00232827 BTC. Zcash (ZEC) traded 2.6% lower against the dollar and now trades at $200.83 or 0.02690330 BTC. Bytecoin (BCN) traded 3.7% lower against the dollar and now trades at $0.0032 or 0.00000043 BTC. Bitcoin Gold (BTG) traded down 0.7% against the dollar and now trades at $30.86 or 0.00413388 BTC. DigiByte (DGB) traded 14.4% higher against the dollar and now trades at $0.0475 or 0.00000637 BTC.

Blakecoin Profile

Blakecoin (CRYPTO:BLC) is a proof-of-work (PoW) coin that uses the
Blake-256 hashing algorithm. It launched on October 6th, 2013. Blakecoin’s total supply is 18,815,378 coins. Blakecoin’s official Twitter account is @BlakeCoin. Blakecoin’s official website is www.blakecoin.org.

Blakecoin Coin Trading

Blakecoin can be purchased on these cryptocurrency exchanges: Cryptopia and C-Patex. It is usually not presently possible to buy alternative cryptocurrencies such as Blakecoin directly using U.S. dollars. Investors seeking to trade Blakecoin should first buy Ethereum or Bitcoin using an exchange that deals in U.S. dollars such as Coinbase, Changelly or Gemini. Investors can then use their newly-acquired Ethereum or Bitcoin to buy Blakecoin using one of the aforementioned exchanges.

new TradingView.widget({ “height”: 400, “width”: 650, “symbol”: “BLCUSD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Thursday, July 12, 2018

Why Procter & Gamble Stock Has Lost 15% in 2018

What happened

Returns for Procter & Gamble (NYSE:PG) shareholders have underperformed the market through the first six months of 2018. The stock fell 15% in that period as the S&P 500 gained 2%, according to data provided by S&P Global Market Intelligence.

^SPX Chart

^SPX data by YCharts.

The slump has contributed to a rough run for P&G investors, who've seen their shares stay flat over the past five years compared to a 69% spike in the broader market.

So what

P&G's big problem has been sluggish sales growth. Its revenue ticked up by just 1% in the most recent quarter to mark a slowdown from the prior quarter's disappointing 2% increase. In explaining the results, CEO David Taylor cited pricing pressures across the consumer staples industry. "The ecosystems in which we operate around the world," Taylor said, "are being disrupted and transformed."

A woman holds a bottle of laundry detergent in front of shelves with cleaning products.

Image source: Getty Images.

Now what

The good news: Procter & Gamble's costs are still trending lower. It remains a fantastically efficient business that generates tons of free cash flow and market-leading profitability, too. These characteristics support ample cash returns to shareholders in the form of dividends and share buybacks.

Yet the multiyear slump in the stock isn't likely to end until the owner of the Pampers and Gillette franchises can use those brands to return to at least modest market-share growth.

Wednesday, July 11, 2018

Here's the Only Way to Play President Trump's Trade Wars

Tom GentileTom Gentile

In case you've missed the news, President Trump's trade wars have officially begun.

After months of circulating rumors and political rhetoric, a 25% levy on $34 billion of Chinese goods entering the United States took effect just after midnight on July 6.

And neither side is showing any signs of backing down, as China immediately slapped U.S. shipments with "retaliatory" tariffs.

Now, as you might guess, this could cause quite the disruption in an already volatile and uncertain market – especially when you don't know when the next set of retaliatory tariffs might hit.

So here's everything you need to know to survive even the worst of the trade wars…

A New Way to Trade

Over the last few weeks, I've sent you trading strategies to help you navigate any kind of market.

But today, I want to focus on options.

Now, we all know about the opinions surrounding them: Stay away from options, options are too big of a risk, and more. But the truth is, options are the best way to make money in any market. Yet there's a right way and a wrong way to�approach these lucrative opportunities.

And it starts with this one, simple rule: Plan your trade and trade your plan.

This sounds easy enough – and it is.

But there's a little more to managing your trades than you might initially think…

Trade management involves using price and time targets to maximize your profits and minimize your losses. And the best way to do that is to establish these targets first.

Your price target is the price you need the stock, exchange-traded fund (ETF), commodity, or whatever you're trading to hit in order to capture profits. Your time target is the time frame in which you need to hit your price target. You can set both of these targets easily by looking at a stock's past price moves and patterns and eyeballing the time frames in which the price moves you need�have�happened.

When you've got your plan in place and stick to your guns, you can feel confident about what you're doing and can set yourself up to make money no matter if the markets go up, down, or sideways. It also allows you to remove the emotion from trading and investing that can potentially sabotage your profit opportunities. It gives you control of the markets instead of leaving you at their mercy.

LIVE ON CAMERA: Watch America's No. 1 Pattern Trader officially become $1,050 richer in 15 seconds! His secret to becoming a multimillionaire is so easy that anybody can do it. Click here for details…

You shouldn't change the way you trade regardless of the market temperature. So shut out the fear of missing out, the talking heads, the flashing red headlines, and the constant dialogue about the "next big market crash" – and follow your rules and strategies.

The profits will come quicker than you can imagine.

But that's not the only little trick to success.

It's easy to know your rules once you get into a trade – but knowing which position is best to take can be harder.

Don't worry – I've got you covered…

Join the conversation. Click here to jump to comments…

Tom GentileTom Gentile

About the Author

Browse Tom's articles | View Tom's research services

Tom Gentile is one of the world's foremost authorities on stock, futures and options trading.

With more than 25 years' experience trading stocks, futures, and options, Tom's style of trading systems and strategies are designed to help individual investors propel themselves past 99 percent of the trading crowd.

… Read full bio

Monday, July 9, 2018

Reviewing FirstCash (FCFS) & CafePress (PRSS)

FirstCash (NYSE: FCFS) and CafePress (NASDAQ:PRSS) are both finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Earnings & Valuation

Get FirstCash alerts:

This table compares FirstCash and CafePress’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
FirstCash $1.78 billion 2.32 $143.89 million $2.74 33.18
CafePress $85.68 million 0.25 -$10.25 million N/A N/A

FirstCash has higher revenue and earnings than CafePress.

Institutional and Insider Ownership

95.5% of FirstCash shares are held by institutional investors. Comparatively, 8.3% of CafePress shares are held by institutional investors. 2.8% of FirstCash shares are held by company insiders. Comparatively, 17.3% of CafePress shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

FirstCash has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, CafePress has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Profitability

This table compares FirstCash and CafePress’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
FirstCash 8.58% 9.56% 6.74%
CafePress -12.80% -29.35% -22.99%

Dividends

FirstCash pays an annual dividend of $0.88 per share and has a dividend yield of 1.0%. CafePress does not pay a dividend. FirstCash pays out 32.1% of its earnings in the form of a dividend.

Analyst Recommendations

This is a summary of current recommendations and price targets for FirstCash and CafePress, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FirstCash 0 3 3 0 2.50
CafePress 0 0 0 0 N/A

FirstCash presently has a consensus price target of $83.80, suggesting a potential downside of 7.81%. Given FirstCash’s higher possible upside, analysts clearly believe FirstCash is more favorable than CafePress.

Summary

FirstCash beats CafePress on 11 of the 13 factors compared between the two stocks.

About FirstCash

FirstCash, Inc. operates retail-based pawn and consumer finance stores in the United States and Mexico. Its pawn stores lend money on the collateral of pledged personal property, including consumer electronics, jewelry, power tools, household appliances, sporting goods, and musical instruments; and retails previously owned merchandise acquired through pawn forfeitures, as well as through purchases from the general public. The company also engages in melting scrap jewelry, as well as sells the gold, silver, and diamonds in commodity markets. Its consumer finance stores provide small unsecured consumer loans, credit services, and check cashing services. As of December 31, 2017, the company owned and operated 2,039 pawn stores and 72 consumer loan stores in 26 states of the United States and 32 states of Mexico, as well as Guatemala and El Salvador. The company was formerly known as First Cash Financial Services, Inc. and changed its name to FirstCash, Inc. in September 2016. FirstCash, Inc. was founded in 1988 and is headquartered in Fort Worth, Texas.

About CafePress

CafePress Inc. operates as retailer of personalized products in the United States and internationally. The company offers gifts and accessories, including T-shirts and apparel; mugs and drinkware; and home goods, such as custom shower curtains and bed coverings. It conducts its business on its primary United States based domain, CafePress.com; and operates CafePress branded Websites for the markets in the United Kingdom, Canada, and Australia. The company also sells CafePress branded products through other online retail partners. The company was formerly known as CafePress.com, Inc. and changed its name to CafePress Inc. in June 2011. CafePress Inc. was founded in 1999 and is headquartered in Louisville, Kentucky.

Friday, July 6, 2018

Top 5 Stocks To Buy Right Now

tags:IMMU,AGX,NRE,FB,VBLT,

Quotient (NASDAQ:QTNT) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Tuesday.

Several other analysts also recently weighed in on the company. Zacks Investment Research downgraded Quotient from a “hold” rating to a “strong sell” rating in a research note on Saturday, June 2nd. BidaskClub upgraded Quotient from a “hold” rating to a “buy” rating in a research note on Thursday, May 31st. Finally, BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of Quotient in a research note on Wednesday, May 30th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $11.50.

Top 5 Stocks To Buy Right Now: Immunomedics, Inc.(IMMU)

Advisors' Opinion:
  • [By Todd Campbell]

    After unveiling positive results for its lead drug, sacituzumab govitecan, in breast cancer at the influential American Society of Clinical Oncology (ASCO) conference, shares in Immunomedics (NASDAQ:IMMU) rallied by as much as 14.7% today before settling in for a gain of 9.3% at 3 p.m. EDT.

  • [By Ethan Ryder]

    Teachers Advisors LLC increased its position in shares of Immunomedics (NASDAQ:IMMU) by 14.9% in the 4th quarter, HoldingsChannel reports. The firm owned 211,706 shares of the biopharmaceutical company’s stock after purchasing an additional 27,385 shares during the period. Teachers Advisors LLC’s holdings in Immunomedics were worth $3,421,000 at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Celldex Therapeutics (NASDAQ: CLDX) and Immunomedics (NASDAQ:IMMU) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

  • [By Logan Wallace]

    Rock Springs Capital Management LP bought a new position in Immunomedics, Inc. (NASDAQ:IMMU) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 450,000 shares of the biopharmaceutical company’s stock, valued at approximately $6,575,000. Rock Springs Capital Management LP owned 0.27% of Immunomedics at the end of the most recent reporting period.

  • [By Logan Wallace]

    Immunomedics, Inc. (NASDAQ:IMMU) Director Venbio Select Advisor Llc bought 575,000 shares of the company’s stock in a transaction on Friday, June 15th. The stock was bought at an average cost of $24.00 per share, for a total transaction of $13,800,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Top 5 Stocks To Buy Right Now: Argan, Inc.(AGX)

Advisors' Opinion:
  • [By Max Byerly]

    Federated Investors Inc. PA raised its position in Argan, Inc. (NYSE:AGX) by 26.6% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 99,678 shares of the construction company’s stock after buying an additional 20,936 shares during the period. Federated Investors Inc. PA’s holdings in Argan were worth $4,282,000 as of its most recent filing with the SEC.

  • [By Joseph Griffin]

    State Board of Administration of Florida Retirement System decreased its holdings in Argan, Inc. (NYSE:AGX) by 26.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,343 shares of the construction company’s stock after selling 1,907 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Argan were worth $229,000 at the end of the most recent reporting period.

Top 5 Stocks To Buy Right Now: NorthStar Realty Europe Corp.(NRE)

Advisors' Opinion:
  • [By Shane Hupp]

    Teachers Insurance & Annuity Association of America increased its holdings in NorthStar Realty Europe (NYSE:NRE) by 15.7% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 71,499 shares of the financial services provider’s stock after purchasing an additional 9,699 shares during the period. Teachers Insurance & Annuity Association of America owned approximately 0.13% of NorthStar Realty Europe worth $931,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    NorthStar Realty Europe (NYSE:NRE) has been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $17.17.

  • [By Joseph Griffin]

    Northstar Realty Europe Corp (NYSE:NRE) has earned an average rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $16.83.

Top 5 Stocks To Buy Right Now: Facebook, Inc.(FB)

Advisors' Opinion:
  • [By Javier Hasse]

    Overall, Traackr found that while Twitter Inc (NYSE: TWTR) garners about half the mentions of cannabis brands by influencers on social media, Facebook, Inc. (NASDAQ: FB)’s Instagram down the platform that drives the most engagement for brands. The only exception is represented by the vaporizers category, which have generated significant conversation on Alphabet Inc (NASDAQ: GOOGL)’s YouTube.

  • [By Wayne Duggan]

    On this day six years ago, Facebook, Inc. (NASDAQ: FB) held its highly anticipated IPO.

    Where The Market Was

    The Dow finished the day at 12,369.38. The S&P 500 traded at 1,295.22. Today, the Dow is trading at 24,713.98 and the S&P 500 is trading at 2,720.13.

  • [By Michael A. Robinson]

    Make no mistake. Each member of the FANG Plus group is a great company. We're talking Facebook Inc. (Nasdaq: FB), Amazon.com Inc. (Nasdaq: AMZN), Netflix Inc. (Nasdaq: NFLX), and Alphabet Inc. (Nasdaq: GOOGL) – plus Apple Inc. (Nasdaq: AAPL).

  • [By Evan Niu, CFA]

    The Cambridge Analytica privacy scandal continues to engulf Facebook (NASDAQ:FB), with CEO Mark Zuckerberg set to testify to Congress this week in what promises to be an epic grilling. Zuckerberg's defense�that "Facebook is an idealistic and optimistic company" and never gave serious consideration to how its platform could be hijacked for malicious purposes is rather naive.

  • [By Alison Southwick and Robert Brokamp, CFP]

    In this episode of Motley Fool Answers, Robert Brokamp and Alison Southwick are joined by Matt Argersinger of Million Dollar Portfolio and Supernova to talk about the powerful and popular FAANG stocks, which over the longer term -- and particularly, the last five years -- have delivered stellar returns to shareholders. But the past few months have brought trouble and upheaval to the tech sector, and public response to privacy problems could put a crimp in the progress of companies like Facebook�(NASDAQ:FB) and Alphabet�(NASDAQ:GOOGL) (NASDAQ:GOOG).

  • [By Michael A. Robinson]

    Based on the early days of what eventually became Facebook Inc. (Nasdaq: FB), the movie portrayed Zuckerberg as not only brilliant – but also as an egomaniac with a talent for making enemies.

Top 5 Stocks To Buy Right Now: Vascular Biogenics Ltd.(VBLT)

Advisors' Opinion:
  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers ReTo Eco-Solutions, Inc. (NASDAQ: RETO) fell 9.3 percent to $4.50 in pre-market trading. ProPhase Labs, Inc. (NASDAQ: PRPH) shares fell 8.5 percent to $4.50 in pre-market trading after dropping 3.53 percent on Thursday. Nordstrom, Inc. (NYSE: JWN) fell 7.5 percent to $47.10 in pre-market trading. Nordstrom reported upbeat results for its first quarter. Comparable-store sales rose 0.6 percent. Baidu, Inc. (NASDAQ: BIDU) shares fell 6 percent to $263.00 in pre-market trading. Baidu disclosed that its COO Qi Lu will step down in July 2018. Riot Blockchain, Inc. (NASDAQ: RIOT) shares fell 5.6 percent to $8.98 in pre-market trading after climbing 11.88 percent on Thursday. Applied Materials, Inc. (NASDAQ: AMAT) fell 5 percent to $51.30 in pre-market trading. Applied Materials reported stronger-than-expected results for its second quarter, but issued weak sales outlook for the third quarter. Blink Charging Co. (NASDAQ: BLNK) fell 5 percent to $7.61 in pre-market trading after rising 11.40 percent on Thursday. Illumina, Inc. (NASDAQ: ILMN) shares fell 4.7 percent to $255.77 in pre-market trading. Vascular Biogenics Ltd (NASDAQ: VBLT) fell 4.6 percent to $2.10 in pre-market trading after reporting a first-quarter earnings miss. Campbell Soup Company (NYSE: CPB) fell 3.3 percent to $37.60 in pre-market trading. Campbell Soup reported upbeat Q3 earnings, but sales missed estimates. The company also lowered its FY18 outlook. ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares fell 2.7 percent to $17.65 in pre-market trading after reporting a 7.2 million common stock offering
  • [By Lisa Levin] Companies Reporting Before The Bell Walmart Inc. (NYSE: WMT) is estimated to report quarterly earnings at $1.13 per share on revenue of $120.51 billion. J. C. Penney Company, Inc. (NYSE: JCP) is expected to report quarterly loss at $0.2 per share on revenue of $2.63 billion. Dillard's, Inc. (NYSE: DDS) is projected to report quarterly earnings at $2.77 per share on revenue of $1.46 billion. The Children's Place, Inc. (NASDAQ: PLCE) is estimated to report quarterly earnings at $2.21 per share on revenue of $444.14 million. Manchester United plc (NYSE: MANU) is expected to report quarterly loss at $1.35 per share on revenue of $193.67 million. Teekay Corporation (NYSE: TK) is estimated to report quarterly loss at $0.08 per share on revenue of $296.76 million. KEMET Corporation (NYSE: KEM) is projected to report quarterly earnings at $0.41 per share on revenue of $306.72 million. Vascular Biogenics Ltd. (NASDAQ: VBLT) is estimated to report a quarterly loss at $0.21 per share. Teekay Offshore Partners L.P. (NYSE: TOO) is expected to report quarterly earnings at $0.04 per share on revenue of $272.04 million. Albireo Pharma, Inc. (NASDAQ: ALBO) is expected to report quarterly earnings at $1.77 per share on revenue of $31.32 million.

     

Monday, July 2, 2018

10,859 Shares in Clearside Biomedical Inc (CLSD) Purchased by MetLife Investment Advisors LLC

MetLife Investment Advisors LLC purchased a new position in shares of Clearside Biomedical Inc (NASDAQ:CLSD) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,859 shares of the company’s stock, valued at approximately $117,000.

Several other institutional investors have also recently modified their holdings of CLSD. Deutsche Bank AG increased its stake in shares of Clearside Biomedical by 33.8% during the fourth quarter. Deutsche Bank AG now owns 47,523 shares of the company’s stock worth $331,000 after acquiring an additional 12,012 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Clearside Biomedical by 29.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 47,378 shares of the company’s stock worth $332,000 after acquiring an additional 10,707 shares during the period. Paloma Partners Management Co acquired a new position in shares of Clearside Biomedical during the fourth quarter worth about $124,000. Millennium Management LLC acquired a new position in shares of Clearside Biomedical during the fourth quarter worth about $178,000. Finally, Northern Trust Corp increased its stake in shares of Clearside Biomedical by 8.7% during the first quarter. Northern Trust Corp now owns 243,398 shares of the company’s stock worth $2,611,000 after acquiring an additional 19,476 shares during the period. Institutional investors and hedge funds own 61.48% of the company’s stock.

Get Clearside Biomedical alerts:

In related news, Director Clay Thorp sold 161,139 shares of the business’s stock in a transaction dated Friday, May 18th. The shares were sold at an average price of $13.08, for a total transaction of $2,107,698.12. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Daniel H. White purchased 11,000 shares of Clearside Biomedical stock in a transaction on Monday, June 4th. The stock was acquired at an average cost of $9.07 per share, for a total transaction of $99,770.00. Following the acquisition, the insider now directly owns 472,335 shares of the company’s stock, valued at $4,284,078.45. The disclosure for this purchase can be found here. 15.40% of the stock is currently owned by insiders.

A number of research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. JMP Securities set a $25.00 price target on shares of Clearside Biomedical and gave the stock a “buy” rating in a research note on Saturday, June 9th. Janney Montgomery Scott assumed coverage on shares of Clearside Biomedical in a research note on Thursday. They set a “buy” rating on the stock. BidaskClub lowered shares of Clearside Biomedical from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 8th. Finally, Wedbush reiterated an “outperform” rating and set a $29.00 price target on shares of Clearside Biomedical in a research note on Friday, May 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $20.80.

CLSD stock opened at $10.69 on Friday. Clearside Biomedical Inc has a 52 week low of $5.30 and a 52 week high of $15.33. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.46 and a quick ratio of 7.46.

Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings data on Wednesday, May 9th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.05). Clearside Biomedical had a negative return on equity of 131.37% and a negative net margin of 17,094.20%. analysts expect that Clearside Biomedical Inc will post -2.39 earnings per share for the current fiscal year.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

Want to see what other hedge funds are holding CLSD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clearside Biomedical Inc (NASDAQ:CLSD).

Institutional Ownership by Quarter for Clearside Biomedical (NASDAQ:CLSD)